Modalis Therapeutics Corporation (TSE: 4883)
Health Care · Biotechnology · JP
¥29.00
-3.33% today · -62.3% 1Y
Modalis Therapeutics Corporation (TSE: 4883) operates in the Biotechnology industry within the Health Care sector. The company is valued at $19.56M and employs 17 people.
Over the last twelve months the share price has lost 62.3%, trading between 28.00 and 83.00.
Tweenvest scores Modalis Therapeutics Corporation across four factors: quality 38/100, value 19/100. Its strongest factor is quality.
4883 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $19.56M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -23.61
- Dividend yield
- —
- Beta (5Y)
- 0.41
- 52-week high
- ¥83.00
- 52-week low
- ¥28.00
- Avg volume (3M)
- —
- Shares outstanding
- 106.46M
- Employees
- 17
- Next earnings
- —
About Modalis Therapeutics Corporation
Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.
- ISIN
- JP3922600006
- Founded
- 2016
- Listed since
- Aug 3, 2020
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| ProBiotix Health PlcOFEX: PBX | $20.57M | £0.10 | +2.63% |
| Taiwan Advance Bio-Pharmaceutical Inc.TPEX: 4186 | $20.25M | NT$7.30 | -3.31% |
| BCAL Diagnostics LimitedASX: BDX | $20.15M | AU$0.08 | -12.22% |
| MDxHealth SANasdaqCM: MDXH | $19.71M | $0.21 | -64.97% |
| Elicera Therapeutics AB (publ)OM: ELIC | $19.51M | Skr2.90 | +5.08% |
| Nexsen LimitedASX: NXN | $19.50M | AU$0.14 | +7.69% |
| Resverlogix Corp.TSX: RVX | $19.47M | CA$0.08 | -5.88% |
| Inhibitor Therapeutics, Inc.OTCPK: INTI | $19.10M | $0.11 | +12.14% |
Figures last refreshed Oct 18, 2026.